New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan 1 vs Dulaglutide

Melanotan 1 vs Dulaglutide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticSexual Health & Libido
Melanotan 1
GLP-1 / Weight Loss Agonists
Dulaglutide
Summary
Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
Half-Life
~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
~5 days
Admin Route
SubQ
SubQ
Research
Typical Dose
0.5–1 mg
0.75 mg → 1.5 mg
Frequency
Daily until desired color achieved, then maintenance
Once weekly
Key Benefits
  • Induces skin pigmentation/tanning without UV exposure
  • Provides photoprotection in photosensitivity conditions (EPP)
  • FDA-approved for erythropoietic protoporphyria (SCENESSE)
  • Approved in EU for EPP treatment
  • Anti-inflammatory via MC1R
  • Mild libido enhancement
  • Potential skin cancer prevention through melanin protection
  • FDA-approved for type 2 diabetes
  • Once-weekly subcutaneous dosing via auto-injector pen
  • Reduces HbA1c by approximately 1.1–1.6%
  • Modest weight loss of 1.5–3 kg at approved doses
  • Demonstrated cardiovascular risk reduction (REWIND trial)
  • Established long-term safety profile
  • Renal protective effects in CKD
Side Effects
  • Nausea (especially at higher doses)
  • Facial flushing
  • Fatigue
  • Injection site reactions
  • +3 more
  • Nausea (most common, typically transient)
  • Diarrhea
  • Vomiting
  • Decreased appetite
  • +3 more
Stacks With